FDA Warning Letter on a Drug Manufacturing Facility in South Korea
This time we focus on a drug manufacturing facility in South Korea, issued a Warning Letter on June 12, 2024 Inadequate Validation of Manufacturing Processes The facility failed to adequately validate manufacturing processes for their over-the-counter (OTC) drug product. This includes insufficient data to demonstrate process validation and equipment qualification. Corrective Actions –…
